Zymeworks

Zai Lab (ZLAB) is one of the most polarizing stocks in the mid-cap biotech segment in 2026: a Shanghai-operated biopharma listed in the US, with a pipeline mostly built on Western in-licensings — and a share price 53 % below the 52-week high of $44.34. At the current $20.59 the stock is just 16 % above the 52-week low. The market is pricing in structural geopolitical skepticism, not operational weakness.

Operationally, the story is strong: revenue +17 % YoY to $460M, core products are Zejula (PARP inhibitor for ovarian cancer, licensed from GSK) and VYVGART (Argenx, myasthenia gravis) — the latter is Zai Lab's growth lever with estimated peak sales above $1B in the China market alone. On top: 6 Phase 3 assets and 4 additional commercial products.

The problem: Zai Lab hasn't been profitable since its 2014 founding and likely won't be in 2026 either — EPS −$1.70, operating margin −54.4 %. Management targets break-even in 2027 and cash on hand supports the burn through that date. But: smart money (Buffett, Burry, Druckenmiller) holds zero. For a China ADR with active Trump-era delisting risk in 2026, that's a meaningful signal.

In the current 13F universe, none of the BMI-tracked smart money managers (Burry, Buffett, Druckenmiller, Ackman, Tepper) holds a ZLAB position. That's unusual for a $2.3B growth-biotech mid-cap — comparable US biotechs like Argenx or Vertex have much higher hedge-fund allocation.

Who's actually long: Chinese healthcare specialists like Hillhouse Capital (~7 % stake via Hong Kong listing 9688.HK) and Sequoia China. On the US side the largest positions are with Capital Group (~9 %) and BlackRock (~6 %) — passive index holders, not conviction buys.

Insider activity: CEO Samantha Du sold 250,000 shares in March 2026 at $22 (10b5-1 plan). No unusual insider buying in the past 12 months — for a stock 53 % off its high, insider accumulation would be the clearest confidence signal, and it isn't there.

Zai Lab trades at EV/sales 4.8× — historically low, but for an unprofitable mid-cap biotech with a China discount not really cheap. Comparables: BeiGene (BGNE) at 6.1× EV/sales, Innovent (1801.HK) at 5.2×. Forward P/S drops to 4.1× in 2026 — if VYVGART growth holds. P/B 3.18 — book value barely matters here because goodwill and in-process R&D assets dominate the balance sheet. DCF fair-value with 12 % WACC, 18 % CAGR through 2030, break-even 2027: $26–$32. That broadly matches the analyst median of $34 — but NOT the current $20.59 price, which embeds a roughly 25 % geopolitical risk discount. Anyone buying today implicitly bets that this discount narrows.

1. July 30, 2026 (estimated): Q2 2026 earnings — critical for VYVGART China run-rate and NRDL volume effect
2. Q3 2026: NMPA approval decision for TIVDAK (tisotumab vedotin, cervical cancer) in China
3. Q4 2026: ZL-1310 Phase 2 data readout (anti-DLL3 ADC for SCLC) — potential out-licensing trigger

Zai Lab is the rare stock where I'm operationally optimistic and politically skeptical at the same time. The VYVGART China ramp is real, the Argenx partnership is first-class, and management has executed consistently since IPO. But: under an HFCAA delisting I'd suddenly be in a 9688.HK position with no trading volume — that risk isn't hypothetical, it's actively in the DC discourse in 2026. My take: maximum 1.5 % portfolio allocation, and only as a China biotech trade with a clear stop at $16.50 (just under the 52-week low). Anyone after a pure VYVGART story should buy Argenx (ARGX) directly — same growth without the China risk premium.